Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Eculizumab (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 09 Aug 2017 Status changed from recruiting to completed.
- 06 Dec 2016 Preliminary results (n=7) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 07 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.